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Abstract
Background: Frequent and indiscriminate use of antibiotics has led to the development of multi-drug resistant
bacterial strains. It necessitates the exploitation of alternative therapeutic strategies. In order to reduce the dose of
antibiotic required and to decrease the associated side effects, the present study was aimed at evaluating the
synergism, if any, between a conventional antibiotic, co-trimoxazole (CTZ)) and cell free supernatant (CFS) of a
probiotic (L. plantarum) against S. Typhimurium NCTC 74. This antimicrobial combination was selected on the basis
of antibiotic susceptibility pattern of Salmonella and L. plantarum.
Methods: The synergy was evaluated in terms of size of zone of inhibition, fractional inhibitory concentration
index, time-kill assay (in-vitro) as well as macrophage functions (ex-vivo).
Results: The concentration producing the same or higher antibacterial effect (size of zone of inhibition) was
reduced to half when both the agents were used in combination with respect to the concentrations required
when used separately. CTZ and CFS exhibited synergetic activity against Salmonella by checkerboard microtitre test
and the time-kill test. Ex-vivo studies demonstrated a significantly higher intracellular killing of bacteria by
macrophages treated with CFS (80 AU/ml) + (CTZ) (2 μg/ml) as compared to when treated with both separately at
higher concentrations. Significant reduction in the extent of lipid peroxidation and nitrite levels generated by
macrophages in presence of CFS and CTZ, in conjunction, further substantiated the synergistic efficacy of the
combination.
Conclusions: The antimicrobial efficacy of this combination indicates that it may serve as the basis in developing
alternative strategies to combat Salmonella infections.
Background
Salmonella infections cause a great deal of morbidity
and mortality worldwide, especially in developing coun-
tries because of improper sanitary conditions and inade-
quate health facilities. Antibiotics have been the
mainstay of therapy to combat Salmonella infections.
However, the use of antibiotics is under question due to
complications involving the emergence of multidrug
(MDR) resistant strains of Salmonella [1,2]. Besides this,
frequent and lengthy use of antibiotics usually results in
alteration of the intestinal commensal flora [3] and lead
to chronic toxicity. It necessitates the exploitation of
alternative antibacterial therapies against Salmonella
infections. Synergistic combinations of antibiotics and
other antimicrobials may be effective not only against
infections where the development of resistance and/or
subsequent failure to monotherapy is prevalent but also
in prevention of emergence of bacterial resistance [4].
One such alternative is the possible therapeutic use of
probiotics as an adjunct to chemotherapy [5].
Probiotics are dietary supplements containing poten-
tially beneficial bacteria or yeasts. According to the cur-
rently adopted definition by FAO/WHO in 2001,
probiotics are ‘live microorganisms, which when admi-
nistered in adequate amounts confer a health benefit on
the host’ [6]. The role of probiotics has been reported in
prevention and treatment of gastrointestinal infections
caused by Salmonella [7,8], rotavirus and Clostridium
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any medium, provided the original work is properly cited.difficile [9-11]. Probiotics in combination with antibiotic
treatment have been reported to be successful in the
management of Helicobacter pylori infection [12].
Probiotic and antibiotic combinatorial therapy may
provide higher antimicrobial activity and reduce the
dose of antibiotic required besides replenishing the
intestinal flora thereby providing benefit to the host
[13]. The present study was therefore carried out to
assess the in-vitro and ex-vivo synergistic effect, if any,
of cell-free Lactobacillus plantarum supernatant (CFS)
in conjunction with co-trimoxazole (CTZ) against
Salmonella Typhimurium.
Methods
Bacterial strains and growth conditions
Lactobacillus casei MTCC 1423, Lactobacillus
plantarum MTCC 2621 and Lactobacillus acidophilus
MTCC 447, standard LAB strains were procured
from Institute of Microbial Technology (IMTECH),
Chandigarh, India. Salmonella enterica serovar Typhi-
murium NCTC74 was procured from the Central
Research Institute (CRI), Kasauli. This strain has been
used in previous studies both as a virulent strain [14]
and as a reference strain [15].
Growth Conditions
Salmonella Typhimurium was maintained on Brain
Heart Infusion Broth and sub-cultured bimonthly. It
was grown on nutrient broth for 18 h at 37°C. After
centrifugation, the culture was harvested in phosphate-
buffered saline (PBS) and adjusted to a final cell count
of approx. 4 × 10
7CFU/ml. Lactobacilli strains were
grown in De Mann Rogosa Sharpe (MRS) broth for
24 h and adjusted to a final concentration of approx.
9×1 0
8CFU/ml. The bacterial strains used in the pre-
sent study were confirmed by their morphological and
biochemical characteristics.
Antibiotic susceptibility tests
All procured strains were tested for their susceptibility to
various antibiotics (μg): Cotrimoxazole (25); Gentamycin
(10); Ampicillin (25); Cephalexin (30); Norfloxacin (10);
Amikacin (30); Cefoxitin (10); Chloramphenicol (10);
Cefuroxine (30); Augmentin (10); Cefotaxime (30);
Ciprofloxacin (10) and Tetracycline (25) by the method
of Bauer et al. [16]. 10
6 colony forming units (CFUs) of
each Lactobacillus strain were spread plated individually
onto MRS agar plate. Hi-media octadiscs impregnated
with antibiotics were placed on the surface of the agar
plates. The plates were incubated at 37°C for 18-24 hrs
and examined for the zones of inhibition appearing
around each antibiotic disc. The experiment was repeated
thrice and the average inhibitory zone diameters were
compared with the standards provided by the National
Committee for Clinical Laboratory Standards (NCCLS)
[17]. Antibiotic sensitivity of Salmonella Typhimurium
was also determined by the same method using nutrient
agar plates.
Agar well diffusion assay (agar-WDA)
As the antibiotic susceptibility pattern indicated that
Lactobacillus plantarum was resistant and Salmonella
Typhimurium was sensitive to co-trimoxazole, the feasi-
bility of using this combination was further confirmed
by agar-WDA [18]. 10
7 CFU of L. plantarum and
S. T y p h i m u r i u mw e r es p r e a dp l a t e do nM R Sa n dn u t r i -
ent agar plates respectively. Wells of 5 mm diameter
were punched in the agar plates and filled with 20 μl
co-trimoxazole stock solution (1 mg/ml). The plates
were then incubated at 37°C for 24 h and observed for
the zones of inhibition around the wells.
Preparation of cell free supernatant (CFS) from
L. plantarum
CFS was prepared as described by Ogunbanwo et al.
[19]. L. plantarum was propagated in 1L MRS broth
(pH 6.5) for 24 hours at 37°C. Cell free supernatant
obtained by centrifuging the culture at 10,000 rpm for
20 minutes at 4°C was filtered through 0.22 μmp o r e
size cellulose acetate filter.
Quantification of antagonistic activity of CFS against
Salmonella Typhimurium
The antibacterial activity of CFS against S. Typhimur-
ium was tested at twofold serial dilutions using agar-
WDA as described above. For this experiment, wells
were filled with 10 μl of each CFS dilution and the anti-
bacterial activity was expressed in terms of arbitrary
unit (AU). It was defined as the maximum dilution
which produced a minimum of zone that still gave a
clearly visible antibacterial zone. The reciprocal of the
dilution gave the titre of antibacterial activity in AU per
mm [20].
In-vitro inhibitory effect of CFS and co-trimoxazole
Agar-well diffusion assay
Nutrient agar plates were spread plated with approx. 10
6
CFUs of S. Typhimurium and the wells were filled with
20 μl solution containing various concentrations of CTZ
(10 μg/ml, 20 μg/ml, 30 μg/ml) and CFS (12 AU/ml,
16 AU/ml and 20 AU/ml) separately as well as in com-
bination of both at half the concentrations i.e. (CTZ
(5 μg/ml) + CFS (6 AU/ml); CTZ (10 μg/ml) + CFS
(8 AU/ml) and CTZ(15 μg/ml) + CFS (10 AU/ml). After
incubation at 37°C for 24 h, diameter of the clear zones
around the wells was measured.
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The minimum inhibitory concentrations (MICs) of CFS
and co-trimoxazole against S. typhimurium were deter-
mined by broth micro-dilution method. Co-trimoxazole
powder (Torque Pharmaceuticals, India) was dissolved at
a maximum concentration of 1 mg/ml in distilled water
for MIC determination. The maximum concentration of
CFS was 1280 AU/ml for MIC determination. Co-tri-
moxazole and CFS were subjected to a two-fold dilution
series with Mueller-Hinton Broth and LB medium
respectively. 10 μl of each diluted solution was added in
micro-titre plate wells. Then 90 μlo fS. Typhimurium
cell suspension adjusted to 10
6cfu/ml was added to the
wells and microtitre plate was incubated for 24 h at 37°C.
The lowest concentration that completely inhibited
microbial growth as determined by optical density mea-
surements at 600 nm was taken to be the MIC.
Synergistic activity of co-trimoxazole and CFS on
checkerboard micro-titre test
Checkerboard test was performed in 96-well micro-titre
trays using an 8·8 well configuration. Eight 2-fold serial
dilutions of co-trimoxazole and CFS were prepared with
concentrations ranging from 0 to 2 MIC. 10 μlo fC T Z
dilution was added to the wells of a 96-well plate in a verti-
cal orientation and 10 μl of each CFS dilution was added in
a horizontal orientation so that the plate contained various
concentrations of combinations of the two compounds.
Then each well was supplemented with 80 μl( 1 0
6 CFU/
ml) of S. Typhimurium and the plate was incubated at 37°C.
Wells not containing any antibacterial agent were used as
the positive growth controls. Fractional inhibitory concen-
tration (FIC) was calculated by dividing the MIC of the
combination of CFS and CTZ by the MIC of CFS or co-
trimoxazole alone. The FIC index (FICI), obtained by adding
both FIC, was interpreted as indicating a synergistic effect
when it was ≤ 0.5, as additive or indifferent when it was
>0 . 5a n d≤ 2.0, and as antagonistic when it was > 2.0 [21].
Time-kill Assay
To determine the bactericidal action of co-trimoxazole
and CFS, separately and in combination, S. Typhimurium
was exposed to one of the antimicrobial agents or to both
simultaneously and the viable count was monitored. Co-
trimoxazole (2 μg/ml), CFS (80 AU/ml) and their combi-
nation were added to different 20 ml nutrient broth flasks
containing 10
6 CFUs of S. Typhimurium and incubated at
37°C. 100 μl aliquots were withdrawn at at 0 h, 4 h, 8 h, 12
h, 24 h, 28 h, 32 h, 36 h, 48 h and spread plated on Mac-
Conkey agar plates. The plates were incubated at 37°C for
24 hours for enumeration of colony forming units.
Ex-vivo effect of CFS and co-trimoxazole
Extraction of peritoneal macrophages: Murine peritoneal
macrophages were isolated by the method as described
by us earlier [14].
Intracellular killing of S. Typhimurium
Mouse peritoneal macrophages were infected with
S. Typhimurium at a multiplicity of infection of 1:100.
Extensively washed infected macrophages were treated
with minimum inhibitory concentration of both i.e. CFS
(640 AU/ml) and co-trimoxazole (8 μg/ml) separately
and in combination as per fractional inhibitory concen-
trations i.e. (CFS (80 AU/ml) + CTZ (2 μg/ml)). After
every 30, 60 and 90 min of treatment period, treated
and untreated macrophages were pelleted (2000 rpm,
10 min) and lysed with 500 μl of 0.25% TritonX-100.
Lysates were serially diluted and plated on MacConkey
agar medium. After an incubation of 24 h at 37°C, CFUs
were counted [14].
Interaction of macrophages with S. Typhimurium
To assess the extent of lipid peroxidation and to mea-
sure the nitric oxide generation, murine peritoneal
macrophages were interacted with Salmonella (MOI of
1:100) in various groups: Group A: 1.5 ml of macro-
phage suspension (10
5/ml) + 0.8 ml of S. Typhimurium
cell suspension (10
7/ml); Group B: 1.5 ml of macro-
phage suspension (10
5/ml) + 0.8 ml of S. Typhimurium
cell suspension (10
7/ml) + CFS (640 AU/ml); Group C:
1.5 ml of macrophage suspension (10
5/ml) + 0.8 ml
of S. Typhimurium cell suspension (10
7/ml) + CTZ (8
μg/ml); Group D: 1.5 ml of macrophage suspension
(10
5/ml) + 0.8 ml of S. Typhimurium cell suspension
(10
7/ml) + CFS (80 AU/ml) + CTZ (2 μg/ml) for 16 h
in a six-well tissue culture plate at 37°C in CO2 incuba-
t o rf o r1 8h r s .A f t e ri n c u b a t i o n ,l y s i sb u f f e r( 2 0m M
T r i s - H C l ,1 5 0m MN a C l ,1m ME D T A ,1 %T r i t o n
X-100, 1 mM PMSF) was added (1:1 ratio) to all the
wells and the plate was further incubated at 4°C for 20
min. Reaction mixtures form each well were centrifuged
(2,000 rpm, 15 min) and supernatant thus obtained was
used to study the following:
Extent of lipid peroxidation
Quantitative measurement of lipid peroxidation in the
culture supernatants of macrophages was performed as
described by us earlier [22]. The results were expressed
as nanomoles of MDA per milligram of protein, using
the molar extinction coefficient of chromophore
(1.56×10
5M
-1 cm
-1). Protein content of the samples was
estimated by the method as described by Lowry et al.
[23].
Estimation of nitrite concentration
The amount of nitric oxide in cell-free supernatant was
determined by slight modification of the method of
Green et al. [24] as described by us earlier [25]. 100 μl
aliquots of sample were mixed with 400 μl of distilled
water and 500 μl of Griess reagent. The reaction mix-
ture was incubated at room temperature for 10 min.
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Nitrite was quantified using standard graph of sodium
nitrite.
Statistical analysis
Results were expressed as mean ± standard deviation
(SD). The inter group variation was assessed by one way
analysis of variance (ANOVA) followed by Fischer’s LSD
test. Statistical significance of the results was calculated
to at least P < 0.05.
Results
Antibiotic sensitivity pattern of Lactobacilli and S.
Typhimurium
A compatible probiotic-antibiotic combination was found
to be that of L. plantarum and co-trimoxazole.
S. Typhimurium was found to be sensitive to co-trimoxa-
zole while amongst the three Lactobacilli tested, L. plan-
tarum was found to be resistant to the same (Table 1).
Agar well diffusion assay (agar-WDA)
The sensitivity of S. Typhimurium and resistance of
L. plantarum to co-trimoxazole was further confirmed
by agar-WDA. A clear zone of inhibition (15 mm) of
growth of S. T y p h i m u r i u m( F i g u r e1 A )c o u l db e
observed while L. plantarum exhibited complete resis-
tance to co-trimoxazole (Figure 1B). These observations
indicated the feasibility of using CFS of L. plantarum in
conjunction with co-trimoxazole against S. Typhimur-
ium NCTC74.
Quantification of the antagonistic activity
of L. plantarum cell-free supernatant (CFS)
A clear zone of growth inhibition could be observed
around the wells containing CFS indicating that L. plan-
tarum was inhibitory to the growth of S. Typhimurium.
The maximum dilution of the cell-free supernatant that
produced a minimum of antibacterial zone was 1: 1600.
It was therefore estimated that the antagonistic activity
of the cell-free supernatant was 1600 AU/ml.
Agar-WDA
When the wells were filled with 12 AU/ml, 16 AU/ml
and 20 AU/ml of CFS alone, the zone sizes obtained
were 22 mm, 28 mm and 33 mm respectively. Similarly,
co-trimoxazole at 10, 20 and 30 μg/ml concentrations
produced a zone size of 24, 31 and 40 mm respectively.
However, interestingly in combination at half the con-
centrations of both agents i.e. (CTZ (5 μg/ml) + CFS
(6 AU/ml); CTZ (10 μg/ml) + CFS (8 AU/ml); CTZ
(15 μg/ml) + CFS (10 AU/ml), the zone sizes were 32,
34 and 44 mm respectively (Figure 2A-C are representa-
tive figures). The observed zone of growth-inhibition of
Salmonella Typhimurium indicated synergy between the
two as the dose required to give the same antibacterial
effect in terms of size of zone of inhibition was reduced
to approximately half when CFS and co-trimoxazole
were used in combination as compared to when used
individually at different concentrations.
MICs of co-trimoxazole and CFS
The MICs of cotrimoxazole and CFS against Salmonella
Typhimurium were evaluated to be 8 μg/ml and
640 AU/ml respectively.
Fractional inhibitory concentrations (FIC) of co-
trimoxazole and CFS
The inhibitory activity of the combination of co-trimox-
azole and CFS was determined by the FIC index at 64
different combinations. FICI index was ≤ 0.5 indicating
that there is synergistic effect of the combination. When
used together, co-trimoxazole and CFS inhibited the
Table 1 Antibiotic susceptibility pattern of test Lactobacilli strains i.e L. plantarum, L. casei, L. acidophilus and
indicator strain S. Typhimurium as determined by disc-diffusion technique
Antibiotics Conc. ug/disc Test Lactobacillus strains Indicator strain S. Typhimurium
L. acidophilus L. casei L. plantarum
Norfloxacin 10 R R R S
Cotrimoxazole 25 S S R S
Gentamycin 10 S R S S
Ampicillin 25 R S R R
Cephalexin 30 S S S S
Amikacin 30 S R R S
Cefoxitin 10 R R R R
Chloramphenicol 30 S S R S
Cefuroxine 30 S R R S
Augmentin 10 R R R R
Tetracycline 25 S S S S
S-sensitive R-resistant.
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lower concentrations than when applied alone.
Time Kill Assay
After 48 hours, CFS (80 AU/ml) and CTZ (2 μg/ml)
s e p a r a t e l yg a v ead e c r e a s eo f5 . 7 8l o gu n i t sa n d6 . 5l o g
units respectively as compared to control (48 h). How-
ever, when used in combination, (CFS (80 AU/ml) +
CTZ (2 μg/ml), a decrease of 7 log units was observed
after 48 h (Figure 3) indicating the synergetic effect.
Effect on intracellular killing of S. Typhimurium
The mean percentage intracellular killing in presence
of CFS alone at 30, 60 and 90 minutes was 13.7%, 35%
and 48.75% respectively, at p < 0.05. Similarly, when
infected macrophages were treated with co-trimoxazole
alone, the mean intracellular killing was 21.25%, 42.5%
and 63.75% at 30, 60 and 90 minutes respectively (p <
0.01). A higher intracellular killing was observed when
infected macrophages were treated with co-trimoxazole
in conjunction with CFS. In this case, the killing was
Figure 1 Agar-well diffusion assay. (A) Zone of inhibition of growth of S. Typhimurium produced by co-trimoxazole (10 μg/ml) (B) Resistance
exhibited by L. plantarum to co-trimoxazole (10 μg/ml) (agar-well diffusion assay).
Figure 2 (A-C)-Synergy exhibited by CTZ and CFS in terms of size of zones of inhibition produced when used separately and
in combination against S. Typhimurium as determined by agar-WDA.( A )C T Z( 1 0μg/ml) (B) CFS (12 AU/ml) (C) CFS (6 AU/ml) + CTZ
(5 μg/ml).
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92.3% (‡p < 0.001) at 30’,6 0 ’ and 90’ respectively
(Table 2). On the other hand, the intracellular killing
in untreated macrophages was 11.2%, 27.5% and
43.75% at 30, 60 and 90 minutes respectively. The
results indicate that both CFS and co-trimoxazole
might act cooperatively leading to an enhanced killing
of intracellular S. Typhimurium.
Estimation of lipid peroxidation (MDA) levels
No significant decrease in the levels of MDA was
observed when macrophages were interacted with S.
Typhimurium in the presence of CFS and co-trimoxa-
zole alone as compared to the normally interacted
macrophages (in absence of any antimicrobial agent).
However, MDA levels were significantly reduced where
macrophages were interacted with S. Typhimurium in
the presence of CFS and co-trimoxazole in combination
(Figure 4).
Estimation of nitrite levels
Significant decrease (p < 0.01) in the levels of nitrite
reduced by macrophages was observed in presence of
cotrimoxazole as compared to the normal infected
macrophages. Similarly, nitrite levels of infected macro-
phages were significantly reduced in the presence of
CFS also but to a lesser extent (p < 0.05) (Figure 5).
H o w e v e r ,am o r ep r o n o u n ced effect (p < 0.01) was
observed when macrophages were interacted with
S. Typhimurium in the presence of both CFS and co-tri-
moxazole together.
Discussion
Therapy with antimicrobial combinations has been in
use for a long time and is often applied to take advan-
tage of different mechanisms of action of the agents
involved [13]. Co-trimoxazole, a combination of a sulfa-
methoxazole with trimethoprim, is a synergistic combi-
nation, which has been used to treat Salmonellosis [26].
However, some Salmonella strains have been reported
to develop resistance to co-trimoxazole [27,28]. Conse-
quently, the study of co-trimoxazole in combination
with probiotics might prove useful as frequency of
development of microbial resistance to the combination
is likely to be lower than it would be to either agent, if
used alone. Therefore, the current study was carried
out to detect whether cell free supernatant from
L. plantarum in combination with co-trimoxazole ther-
apy would have higher antimicrobial activity against
S. Typhimurium.
Keeping in view the application of probiotics to be
used in conjunction with an antibiotic, the first criteria
which a probiotic strain needs to fulfil is that it should
Figure 3 Time-kill assay.L o g 10 CFU of Salmonella Typhimurium
NCTC 74 at various time intervals in presence of cotrimoxazole (2
μg), CFS (80 AU/ml) alone and in combination i.e CTZ(2 μg/ml) +
CFS (80 AU/ml). Values are expressed as mean ± S.D. of three
individual values. *p < 0.05 vs. CTZ (10 ug/ml) and CFS (12 AU/ml).
Table 2 Effect of CTZ and CFS on intracellular killing of Salmonella Typhimurium NCTC 74 (assessed by isolating
murine peritoneal macrophages from Balb/c mice and interacting them with Salmonella in presence of CFS and CTZ
separately and in combination)
Duration of intra-cellular incubation
(min.)
CFU of S. Typhimurium Mean Percentage Intracellular Killing {(No-
Nt/N0)×100}
Untreated
Macrophages
Treated Macrophages Untreated
Macrophages
Treated
Macrophages
CTZ CFS CTZ
+
CFS
CTZ CFS CTZ
+
CFS
0( N 0) 80×10
7 -- - - - -
30 71×10
7 63×10
7* 69×10
7 60×10
7* † 11.2 21.25 13.7 25
60 58×10
7 46×10
7* 52×10
7* 37×10
7* † 27.5 42.5 35 53.75
90 45×10
7 29×10
7* 41×10
7* 6.1×10
7* ‡ 43.75 63.75 48.75 92.3
Co-trimoxazole-CTZ; Cell free supernatant from L. plantarum - CFS.
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direct killing of the probiotic strain. After evaluating the
resistance and sensitivity of L. plantarum and S. Typhi-
murium respectively to co-trimoxazole, the combination
of cell free supernatant from L. plantarum and co-tri-
moxazole was further tested to evaluate the synergistic
effect against S. Typhimurium. The results exhibited
synergy between the two agents as the dose required to
give the same antibacterial effect in terms of size of zone
of inhibition and colony forming units was reduced to
approximately half as compared to when used individu-
ally at higher doses. CFS contains several antimicrobials
[29], lactic and non-lactic acids as well as hydrogen per-
oxide which kill pathogens [30] while co-trimoxazole is
known to interfere with bacterial folate synthesis [31].
These two mechanisms might have acted cooperatively
with each other leading to a higher bactericidal effect of
the combination. FIC index also further substantiated the
synergism between the two.
The in-vitro synergism observed between CFS and co-
trimoxazole prompted us to investigate the ex-vivo
synergistic efficacy in terms of macrophage functions
keeping in view the intracellular survival ability of Sal-
monella. It is also known that S. Typhimurium infection
of macrophages increases intracellular reactive oxygen
intermediates (ROIs), which in turn increase the expres-
sion of other antimicrobial factors [32]. Thus, signifi-
cantly enhanced killing of the Salmonella in the
presence of CFS and co-trimoxazole, in combination,
might be due to the cooperativity between the macro-
phage antibacterial effectors and the antimicrobial com-
binations used [14]. Corroborating with the present
data, earlier studies have also shown that cell free super-
natants and/or extracts from lactic acid producing bac-
teria may activate macrophages in-vitro thereby
resulting in augmented phagocytic activity [33,34].
Further, a significant decrease in extent of lipid perox-
idation (in terms of MDA level) was also observed in
the presence of CFS and co-trimoxazole both. This indi-
cated that the combination of cell free supernatant and
co-trimoxazole may exhibit the synergistic effect by
scavenging free radicals thereby providing protection
against oxidative damage [7]. In support of our findings,
Lin and Yen [35] have also reported the inhibition of
lipid peroxidation by cell free extracts of L. acidophilus
and B. longum using lipid model systems.
Nitric oxide is an important signalling molecule
which acts in many tissues to regulate diverse range of
physiological process. The estimation of nitrite is an
indirect measure of nitric oxide content. In the present
study also, a significant decrease in nitrite levels was
observed when macrophages were interacted with S.
Typhimurium in presence of both co-trimoxazole and
CFS as compared to infected macrophages in the
absence of the agents. It may be attributed to the
enhanced ability of probiotics to attenuate TNF-a or
TNF-a stimulated IL-8 production in presence of co-
trimoxazole, which might result in further decrease of
NO levels [30,36].
Conclusions
In conclusion, the in-vitro and ex-vivo studies clearly
indicate that cell-free extract from L. plantarum and
co-trimoxazole act synergistically against Salmonella
Typhimurium. Positive effects of this antimicrobial com-
bination against Salmonella points towards possible
Figure 4 Estimation of lipid peroxidation (MDA) levels. Effect on
the levels of lipid-peroxidation (in terms of MDA levels) of
macrophages when infected with S. Typhimurium in presence of co-
trimoxazole and CFS alone and in combination. Values are
expressed as mean ± S.D. of four individual values. *p < 0.05 vs.
Group A.
Figure 5 Estimation of nitrite levels. Effect on the levels of nitrite
levels of macrophages when infected with S. Typhimurium in the
presence of co-trimoxazole, CFS alone or in combination. *p < 0.05
vs. Group A;
≠p < 0.05 vs. Group C;
†p < 0.05 vs. Group B.
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moxazole for effective treatment of Salmonella
infections
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